Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Hudson Value Partners LLC

Hudson Value Partners LLC raised its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 15,856 shares of the medical research company's stock after purchasing an additional 1,071 shares during the period. Amgen accounts for approximately 1.6% of Hudson Value Partners LLC's portfolio, making the stock its 23rd biggest holding. Hudson Value Partners LLC's holdings in Amgen were worth $4,133,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in Amgen in the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 3rd quarter valued at about $29,000. Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the fourth quarter valued at about $36,000. Kennebec Savings Bank acquired a new stake in Amgen during the third quarter worth about $57,000. Finally, PrairieView Partners LLC raised its stake in Amgen by 118.3% during the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company's stock worth $46,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $5.08 during midday trading on Friday, reaching $303.01. The stock had a trading volume of 3,203,645 shares, compared to its average volume of 3,083,469. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a market cap of $162.78 billion, a P/E ratio of 40.13, a P/E/G ratio of 2.55 and a beta of 0.56. The firm has a fifty day simple moving average of $275.62 and a two-hundred day simple moving average of $300.75. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts expect that Amgen Inc. will post 20.6 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. Amgen's dividend payout ratio is currently 126.09%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several analyst reports. StockNews.com cut shares of Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Bank of America increased their price objective on Amgen from $256.00 to $275.00 and gave the stock an "underperform" rating in a research report on Thursday, February 6th. Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $314.09.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,405 shares of company stock worth $10,410,596. 0.69% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.